Difference between revisions of "Involucrin (TG5)"
m |
m |
||
Line 1: | Line 1: | ||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
− | ! | + | ! {infobox header}| '''{{PAGENAME}}''' |
|- | |- | ||
| Substrate peptide name | | Substrate peptide name | ||
Line 51: | Line 51: | ||
| | | | ||
|- | |- | ||
− | | | + | | {infobox header} | |
|- | |- | ||
|} | |} | ||
[[Category:TG5|*]] | [[Category:TG5|*]] |
Latest revision as of 12:07, 10 March 2015
Involucrin (TG5) | |
---|---|
Substrate peptide name | Involucrin |
Synonyms | - |
Determination type | In situ |
Source | Homo sapiens |
Subcellular localization | Cornified envelope |
Swissprot ID | P07476 |
Reactive glutamines | Q288, Q465, Q489, Q495, Q496 |
Reactive lysines | K468, K485, K508 |
Substrate sequence | YLEQQEGQLK
PKNLEQEEKQLELP VKHLEKQEAQLELPE LELPEQQVGQPK LEQQEKHLEHP |
Structure | No available crystal structure |
Surface accessibility | |
Disorder prediction | IUPred |
Reference | PMID:8999895 |
Notes | |